EMCDDA Scientific Committee

EMCDDA Scientific Committee

Introduction: 

The task of the Scientific Committee is to assist the Management Board and the Director of the EMCDDA by delivering an opinion on any scientific matter concerning the Centre's activity which the Management Board or the Director may submit to it. In addition, the risk assessment of new psychoactive substances is carried out by the Scientific Committee, in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended by regulation (EU) 2017/2101).

Label: 
About

Text: 

The EMCDDA Scientific Committee is set up by Article 13 of Regulation (EC) No 1920/2006 of the European Parliament and of the Council on the European Monitoring Centre for Drugs and Drug Addiction (as amended by regulation (EU) 2017/2101).

The task of the Scientific Committee is to assist the Management Board and the Director of the EMCDDA by delivering an opinion on any scientific matter concerning the Centre's activity which the Management Board or the Director may submit to it. In addition, the risk assessment of new psychoactive substances is carried out by the Scientific Committee, in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended by regulation (EU) 2017/2101).

The Committee consists of fifteen well-known scientists appointed by the Management Board in view of their scientific excellence and their independence, following a publication of a call for expressions of interest in the Official Journal of the European Union. The selection procedure ensures that the specialist fields of the members of the Scientific Committee cover the most relevant scientific fields linked to the problems of drug and drug addiction.The members of the Scientific Committee are appointed in a personal capacity and give their opinions completely independently of the Member States and the Community Institutions and serve for a three-year period (renewable).

The Scientific Committee is requested by the EMCDDA founding regulation to give a formal opinion on the EMCDDA programming documents on the basis of a draft submitted by the Centre's Director before it is presented to the Management Board. The Scientific Committee reviews many of the EMCDDA publications with regard to their scientific quality, plays an important role in the risk assessment of new psychoactive substances and supports the different working areas of the EMCDDA. Since its constitution, the Scientific Committee has established itself as an important pillar of the EMCDDA’s institutional life, ensuring the scientific legitimacy of the Centre and providing for continuous improvement of the main outputs.

Minutes from recent Scientific Committee meetings and other reference documents are available under Documents.

Rules of procedure of the EMCDDA Scientific Committee.

Label: 
Members

Text: 

Scientific field Member Affiliation Nationality Specific expertise
Basic biological, neurobiological and behavioural research Dr. Fernando Rodríguez de Fonseca Member

Fundación IMABIS, Málaga, Spain

Spanish Biochemistry, Pharmacology, Neurobiology of drug addiction, Basic research
Basic biological, neurobiological and behavioural research Dr. Marta Torrens Mèlich Member

Universitat Autonoma de Barcelona, Hospital del Mar Medical Research Institute and Neuropsychiatry and Addictions Institute, Consorci Parc de Salut Mar, Barcelona, Spain

Spanish Psychiatry
Demand reduction Prof. Dr. Gabriele Fischer Member

Center of Public Health, Department of Psychiatry & Psychotherapy, Medical University Vienna, Austria

Austrian Psychiatry, Neuroscience, Addiction research, Teaching, Policy and treatment, Public health, Gender research in psychiatry, Human rights
Demand reduction Dr. Laura Amato Member

Department of Epidemiology, Regional Referral centre for Epidemiology of Drug Addiction and evaluation of health care interventions, Lazio, Italy

Italian Epidemiology, Evaluation of health care interventions
Drug policy Dr. Anne Line Bretteville-Jensen Chair

Department of substance use, Norwegian Institute of Public Health, Oslo, Norway

Norwegian Health economics, Economics of addiction, Drug policy, Epidemiology
Drug policy Prof. Dr. Henri Bergeron Member

Centre de Sociologie des Organisations, Sciences Po Paris, Fondation Nationale des Sciences Politiques, Paris, France

French Sociology, Political science and policy evaluation
Drug policy Dr. Marie Jauffret-Roustide Member

Inserm (French Institute of Health and Medical Research), Paris, France

French Sociology, Drug policy, Public health, Ethnicity, Gender issues, Harm reduction, Migration
Drug policy Prof. Dr. Krzysztof Krajewski Member

Jagiellonian University, Department of Criminology, Krakow, Poland

Polish Criminal justice, Legislation, Penal policies, Crime prevention, Criminological theory and violent crime
Population-based research and epidemiology Prof. Dr. Catherine Comiskey Vice-Chair

School of Nursing and Midwifery, Trinity College Dublin, Ireland

Irish Epidemiology, Mathematics, Epidemic modelling, Modelling of treatment outcomes, Incidence and prevalence, Translation of research into policy and practice, Healthcare statistics
Population-based research and epidemiology Prof. Dr. Ilkka Ojanperä Member

Department of Forensic Medicine, University of Helsinki and Forensic Toxicology Unit, Finnish Institute for Health and Welfare, Helsinki, Finland

Finnish Pharmacology & Toxicology
Population-based research and epidemiology Prof. Dr. Margarida Gaspar de Matos Member

Faculdade de Motricidade Humana and Instituto de Saúde Ambiental/Faculdade de Medicina, University of Lisbon, Portugal

Portuguese Epidemiology, Incidence and prevalence
Population-based research and epidemiology Prof. Dr. Matthew Hickman Member

Head of Population Health Sciences, Deputy Head Bristol Medical School, Professor in Public Health and Epidemiology, NIHR Senior Investigator,

Director NIHR Health Protection Research Unit (HPRU) in Behavioural Science and Evaluation. Faculty of Health Sciences, University of Bristol, UK

British Public health and addiction epidemiology, Prevention of health consequences of drug use, HIV, HCV, Drug related mortality, Prevalence estimation methods, Cannabis and health harms, HBV, Evaluation of health care interventions
Population-based research and epidemiology Prof. Dr. Fabrizio Faggiano Member

Department of Translational Medicine of Università del Piemonte Orientale and Epidemiologic Observatory of the Local Health Unit of Vercelli, Italy

Italian Evaluation of effectiveness of prevention interventions, Effective strategies for primary prevention, Dissemination of evidence-based prevention strategies, Healthy ageing
Supply, supply reduction and crime Dr. Kim Moeller Member

Faculty of Health and Society, Department of criminology, Malmö University, Sweden

Danish Criminology, Drug trafficking
Supply, supply reduction and crime Dr. Marieke Liem Member

Institute of Security and Global Affairs, Leiden University, The Netherlands

Dutch Criminology, Clinical psychology
Loading